Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 250

1.

Vasomodulators and liver transplantation for portopulmonary hypertension: evidence from a systematic review and meta-analysis.

Deroo R, Trépo E, Holvoet T, De Pauw M, Geerts A, Verhelst X, Colle I, Van Vlierberghe H, Fallon MB, Raevens S.

Hepatology. 2020 Feb 4. doi: 10.1002/hep.31164. [Epub ahead of print]

PMID:
32017176
2.

Hepatitis C virus (HCV) prevalence estimation in the adult general population in Belgium : a meta-analysis.

Muyldermans G, Bielen R, Botterman R, Bourgeois S, Colle I, Deressa B, Devolder G, Horsmans Y, Hutse V, Lanthier N, Lasser L, Platteau S, Robaeys G, Suin V, Verhelst X, Van Vlierberghe H, Van Baelen L.

Acta Gastroenterol Belg. 2019 Oct-Dec;82(4):479-485.

PMID:
31950802
3.

Combination of sivelestat and N-acetylcysteine alleviates the inflammatory response and exceeds standard treatment for acetaminophen-induced liver injury.

Raevens S, Van Campenhout S, Debacker PJ, Lefere S, Verhelst X, Geerts A, Van Vlierberghe H, Colle I, Devisscher L.

J Leukoc Biol. 2020 Feb;107(2):341-355. doi: 10.1002/JLB.5A1119-279R. Epub 2019 Dec 16.

PMID:
31841237
4.

Protein Glycosylation as a Diagnostic and Prognostic Marker of Chronic Inflammatory Gastrointestinal and Liver Diseases.

Verhelst X, Dias AM, Colombel JF, Vermeire S, Van Vlierberghe H, Callewaert N, Pinho SS.

Gastroenterology. 2020 Jan;158(1):95-110. doi: 10.1053/j.gastro.2019.08.060. Epub 2019 Oct 15. Review.

5.

Update on liver transplantation for cholangiocarcinoma : a review of the recent literature.

Laurent S, Verhelst X, Geerts A, Geboes K, De Man M, Troisi R, Vanlander A, Rogiers X, Berrevoet F, Van Vlierberghe H.

Acta Gastroenterol Belg. 2019 Jul-Sep;82(3):417-420. Review.

PMID:
31566330
6.

Who to screen for hepatitis C? A cost-effectiveness study in Belgium of comprehensive hepatitis C screening in four target groups.

Opstaele L, Bielen R, Bourgeois S, Moreno C, Nevens F, Robaeys G, Robaeys G, Van Vlierberghe H.

Acta Gastroenterol Belg. 2019 Jul-Sep;82(3):379-387.

PMID:
31566325
7.

Caucasian Ethnicity, but Not Treatment Cessation is Associated with HBsAg Loss Following Nucleos(t)ide Analogue-Induced HBeAg Seroconversion.

Van Hees S, Chi H, Hansen B, Bourgeois S, Van Vlierberghe H, Sersté T, Francque S, Wong D, Sprengers D, Moreno C, Nevens F, Janssen H, Vanwolleghem T.

Viruses. 2019 Jul 26;11(8). pii: E687. doi: 10.3390/v11080687.

8.

The potential of glycomics as prognostic biomarkers in liver disease and liver transplantation.

Verhelst X, Geerts A, Callewaert N, Van Vlierberghe H.

Acta Gastroenterol Belg. 2019 Apr-Jun;82(2):309-313. Review.

PMID:
31314193
9.

Unveiling the depletion of Kupffer cells in experimental hepatocarcinogenesis through liver macrophage subtype-specific markers.

Lefere S, Degroote H, Van Vlierberghe H, Devisscher L.

J Hepatol. 2019 Sep;71(3):631-633. doi: 10.1016/j.jhep.2019.03.016. Epub 2019 Jun 15. No abstract available.

PMID:
31213365
10.

Body distribution of stable copper isotopes during the progression of cholestatic liver disease induced by common bile duct ligation in mice.

Costas-Rodríguez M, Van Campenhout S, Hastuti AAMB, Devisscher L, Van Vlierberghe H, Vanhaecke F.

Metallomics. 2019 Jun 19;11(6):1093-1103. doi: 10.1039/c8mt00362a.

PMID:
31021334
11.

Common Bile Duct Ligation as Model for Secondary Biliary Cirrhosis.

Van Campenhout S, Van Vlierberghe H, Devisscher L.

Methods Mol Biol. 2019;1981:237-247. doi: 10.1007/978-1-4939-9420-5_15.

PMID:
31016658
12.

Screening for hepatitis C viral infection in a non-urban primary care facility in Flanders.

Verhelst X, Devolder G, De Wilde M, Goderis L, De Bel A, Spillebeen E, Geerts A, Derese A, Van Vlierberghe H.

Acta Gastroenterol Belg. 2019 Jan-Mar;82(1):99-100. No abstract available.

PMID:
30888763
13.

Sustained off-treatment viral control is associated with high hepatitis B surface antigen seroclearance rates in Caucasian patients with nucleos(t)ide analogue-induced HBeAg seroconversion.

Van Hees S, Chi H, Hansen B, Bourgeois S, Van Vlierberghe H, Sersté T, Francque S, Wong D, Sprengers D, Moreno C, Nevens F, Janssen HLA, Vanwolleghem T.

J Viral Hepat. 2019 Jun;26(6):766-769. doi: 10.1111/jvh.13084. Epub 2019 Mar 14. No abstract available.

PMID:
30801868
14.

Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?

De Bruyn P, Van Gestel D, Ost P, Kruse V, Brochez L, Van Vlierberghe H, Devresse A, Del Marmol V, Le Moine A, Aspeslagh S.

Curr Opin Oncol. 2019 Mar;31(2):54-64. doi: 10.1097/CCO.0000000000000505.

PMID:
30694841
15.

Sociodemographic factors and strategies in colorectal cancer screening: a narrative review and practical recommendations.

Moons L, Mariman A, Vermeir P, Colemont L, Clays E, Van Vlierberghe H, Vogelaers D.

Acta Clin Belg. 2020 Feb;75(1):33-41. doi: 10.1080/17843286.2018.1563736. Epub 2019 Jan 4.

PMID:
30609904
16.

Validation of hepatobiliary transport PET imaging in liver function assessment: Evaluation of 3β-[18F]FCA in mouse models of liver disease.

De Lombaerde S, Devisscher L, Verhoeven J, Neyt S, Van Vlierberghe H, Vanhove C, De Vos F.

Nucl Med Biol. 2019 Jan - Feb;68-69:40-48. doi: 10.1016/j.nucmedbio.2018.12.001. Epub 2018 Dec 8.

PMID:
30595544
17.

Outcome of liver transplantation for hepatopulmonary syndrome: a Eurotransplant experience.

Raevens S, Rogiers X, Geerts A, Verhelst X, Samuel U, van Rosmalen M, Berlakovich G, Delwaide J, Detry O, Lehner F, Mittler J, Nadalin S, Nevens F, Pirenne J, Saner F, Schneeberger S, Stippel D, Turk JM, Zoltan M, Troisi RI, Van Vlierberghe H, Colle I.

Eur Respir J. 2019 Jan 31;53(2). pii: 1801096. doi: 10.1183/13993003.01096-2018. Print 2019 Feb. No abstract available.

18.

Preclinical and Clinical Therapeutic Strategies Affecting Tumor-Associated Macrophages in Hepatocellular Carcinoma.

Degroote H, Van Dierendonck A, Geerts A, Van Vlierberghe H, Devisscher L.

J Immunol Res. 2018 Oct 16;2018:7819520. doi: 10.1155/2018/7819520. eCollection 2018. Review.

19.

Secondary Adrenal Insufficiency after Treatment with Budesonide for Autoimmune Hepatitis.

De Maeyer F, Lapauw B, Hoorens A, Geerts A, Van Vlierberghe H, Verhelst X.

Case Rep Gastroenterol. 2018 Oct 2;12(3):597-601. doi: 10.1159/000492204. eCollection 2018 Sep-Dec.

20.

Angiopoietin-2 Promotes Pathological Angiogenesis and Is a Therapeutic Target in Murine Nonalcoholic Fatty Liver Disease.

Lefere S, Van de Velde F, Hoorens A, Raevens S, Van Campenhout S, Vandierendonck A, Neyt S, Vandeghinste B, Vanhove C, Debbaut C, Verhelst X, Van Dorpe J, Van Steenkiste C, Casteleyn C, Lapauw B, Van Vlierberghe H, Geerts A, Devisscher L.

Hepatology. 2019 Mar;69(3):1087-1104. doi: 10.1002/hep.30294. Epub 2019 Feb 12.

PMID:
30259536
21.

Why Pulse Oximetry Is Inaccurate in Liver Cirrhosis: Ancient Knowledge.

Raevens S, Colle I, Geerts A, Van Vlierberghe H.

Hepatology. 2019 Jan;69(1):462-463. doi: 10.1002/hep.30260. No abstract available.

PMID:
30194847
22.

Endoglycosidase S Enables a Highly Simplified Clinical Chemistry Procedure for Direct Assessment of Serum IgG Undergalactosylation in Chronic Inflammatory Disease.

Vanderschaeghe D, Meuris L, Raes T, Grootaert H, Van Hecke A, Verhelst X, Van de Velde F, Lapauw B, Van Vlierberghe H, Callewaert N.

Mol Cell Proteomics. 2018 Dec;17(12):2508-2517. doi: 10.1074/mcp.TIR118.000740. Epub 2018 Sep 6.

23.

Quantification and isotopic analysis of bulk and of exchangeable and ultrafiltrable serum copper in healthy and alcoholic cirrhosis subjects.

Lauwens S, Costas-Rodríguez M, Delanghe J, Van Vlierberghe H, Vanhaecke F.

Talanta. 2018 Nov 1;189:332-338. doi: 10.1016/j.talanta.2018.07.011. Epub 2018 Jul 6.

PMID:
30086927
24.

Hepatic Changes in the Fontan Circulation: Identification of Liver Dysfunction and an Attempt to Streamline Follow-up Screening.

Ackerman T, Geerts A, Van Vlierberghe H, De Backer J, François K.

Pediatr Cardiol. 2018 Dec;39(8):1604-1613. doi: 10.1007/s00246-018-1937-1. Epub 2018 Jul 21.

PMID:
30032312
25.

Benign anastomotic biliary strictures untreatable by ERCP: a novel percutaneous balloon dilatation technique avoiding indwelling catheters.

Dhondt E, Vanlangenhove P, Van Vlierberghe H, Troisi R, De Bruyne R, Huyck L, Defreyne L.

Eur Radiol. 2019 Feb;29(2):636-644. doi: 10.1007/s00330-018-5526-8. Epub 2018 Jul 6.

PMID:
29980926
26.

Clinical burden of hepatitis E virus infection in a tertiary care center in Flanders, Belgium.

Cattoir L, Van Hoecke F, Van Maerken T, Nys E, Ryckaert I, De Boulle M, Geerts A, Verhelst X, Colle I, Hutse V, Suin V, Wautier M, Van Gucht S, Van Vlierberghe H, Padalko E.

J Clin Virol. 2018 Jun;103:8-11. doi: 10.1016/j.jcv.2018.03.004. Epub 2018 Mar 19.

PMID:
29602096
27.

Severe Hepatic and Pulmonary Involvement in Rendu-Osler-Weber Syndrome.

Verhelst X, Geerts A, Van Vlierberghe H, Smeets P, Lecluyse C.

Case Rep Gastroenterol. 2018 Jan 17;12(1):13-18. doi: 10.1159/000486189. eCollection 2018 Jan-Apr.

28.

Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes.

Van Hees S, Bourgeois S, Van Vlierberghe H, Sersté T, Francque S, Michielsen P, Sprengers D, Reynaert H, Henrion J, Negrin Dastis S, Delwaide J, Lasser L, Decaestecker J, Orlent H, Janssens F, Robaeys G, Colle I, Stärkel P, Moreno C, Nevens F, Vanwolleghem T; Belgian NA Stop Study Group.

Aliment Pharmacol Ther. 2018 Apr;47(8):1170-1180. doi: 10.1111/apt.14560. Epub 2018 Mar 2.

29.

Epidemiology, causes, evolution and outcome in a single-center cohort of 1116 critically ill patients with hypoxic hepatitis.

Van den Broecke A, Van Coile L, Decruyenaere A, Colpaert K, Benoit D, Van Vlierberghe H, Decruyenaere J.

Ann Intensive Care. 2018 Jan 30;8(1):15. doi: 10.1186/s13613-018-0356-z.

30.

Glycome Patterns of Perfusate in Livers Before Transplantation Associate With Primary Nonfunction.

Verhelst X, Geerts A, Jochmans I, Vanderschaeghe D, Paradissis A, Vanlander A, Berrevoet F, Dahlqvist G, Nevens F, Pirenne J, Rogiers X, Callewaert N, Troisi RI, Van Vlierberghe H.

Gastroenterology. 2018 Apr;154(5):1361-1368. doi: 10.1053/j.gastro.2017.12.027. Epub 2018 Jan 6.

PMID:
29309776
31.

The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma.

Pollutri D, Patrizi C, Marinelli S, Giovannini C, Trombetta E, Giannone FA, Baldassarre M, Quarta S, Vandewynckel YP, Vandierendonck A, Van Vlierberghe H, Porretti L, Negrini M, Bolondi L, Gramantieri L, Fornari F.

Cell Death Dis. 2018 Jan 5;9(1):4. doi: 10.1038/s41419-017-0076-6.

32.

Non-alcoholic steatohepatitis induces transient changes within the liver macrophage pool.

Devisscher L, Scott CL, Lefere S, Raevens S, Bogaerts E, Paridaens A, Verhelst X, Geerts A, Guilliams M, Van Vlierberghe H.

Cell Immunol. 2017 Dec;322:74-83. doi: 10.1016/j.cellimm.2017.10.006. Epub 2017 Oct 16.

PMID:
29111158
33.

Placental growth factor inhibition targets pulmonary angiogenesis and represents a therapy for hepatopulmonary syndrome in mice.

Raevens S, Geerts A, Paridaens A, Lefere S, Verhelst X, Hoorens A, Van Dorpe J, Maes T, Bracke KR, Casteleyn C, Jonckx B, Horvatits T, Fuhrmann V, Van Vlierberghe H, Van Steenkiste C, Devisscher L, Colle I.

Hepatology. 2018 Aug;68(2):634-651. doi: 10.1002/hep.29579. Epub 2018 May 11.

PMID:
29023811
34.

Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir Regimen.

Bourgeois S, Horsmans Y, Nevens F, van Vlierberghe H, Moreno C, Beumont M, Vijgen L, van Eygen V, Luo D, Hillewaert V, Van Remoortere P, van de Logt J, Ouwerkerk-Mahadevan S.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01217-17. doi: 10.1128/AAC.01217-17. Print 2017 Dec.

35.

Organ Procurement and Transplantation in Belgium.

Detry O, Van Deynse D, Van Vlierberghe H, Pirenne J; Belgian Transplantation Society (BTS).

Transplantation. 2017 Sep;101(9):1953-1955. doi: 10.1097/TP.0000000000001866. No abstract available.

36.

The PDGFRα-laminin B1-keratin 19 cascade drives tumor progression at the invasive front of human hepatocellular carcinoma.

Govaere O, Petz M, Wouters J, Vandewynckel YP, Scott EJ, Topal B, Nevens F, Verslype C, Anstee QM, Van Vlierberghe H, Mikulits W, Roskams T.

Oncogene. 2017 Nov 23;36(47):6605-6616. doi: 10.1038/onc.2017.260. Epub 2017 Aug 7.

37.

Treatment of a mixed acinar-endocrine carcinoma with uptake on 68Gallium-DOTATOC positron emission tomography-computed tomography: A case report.

De Both A, De Man M, Troisi R, Van Vlierberghe H, Hoorens A, Geboes K.

Oncol Lett. 2017 Jul;14(1):547-552. doi: 10.3892/ol.2017.6242. Epub 2017 May 24.

38.

Belgian experience with direct acting antivirals in people who inject drugs.

Bielen R, Moreno C, Van Vlierberghe H, Bourgeois S, Mulkay JP, Vanwolleghem T, Verlinden W, Brixko C, Decaestecker J, De Galocsy C, Janssens F, Cool M, Van Overbeke L, Van Steenkiste C, D'heygere F, Cools W, Nevens F, Robaeys G.

Drug Alcohol Depend. 2017 Aug 1;177:214-220. doi: 10.1016/j.drugalcdep.2017.04.003. Epub 2017 May 30.

PMID:
28618285
39.

Hepatitis E virus serology and PCR: does the methodology matter?

Cattoir L, Van Hoecke F, Van Maerken T, Nys E, Ryckaert I, De Boulle M, Geerts A, Verhelst X, Colle I, Hutse V, Suin V, Wautier M, Van Gucht S, Van Vlierberghe H, Padalko E.

Arch Virol. 2017 Sep;162(9):2625-2632. doi: 10.1007/s00705-017-3395-0. Epub 2017 May 18.

PMID:
28523520
40.

The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: A Belgian experience.

Bielen R, Moreno C, Van Vlierberghe H, Bourgeois S, Mulkay JP, Vanwolleghem T, Verlinden W, Brixco C, Decaestecker J, de Galocsy C, Janssens F, Van Overbeke L, Van Steenkiste C, D'Heygere F, Cool M, Wuyckens K, Nevens F, Robaeys G.

J Viral Hepat. 2017 Nov;24(11):976-981. doi: 10.1111/jvh.12726. Epub 2017 Aug 3.

PMID:
28504854
41.

Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease.

Lefere S, Van de Velde F, Devisscher L, Bekaert M, Raevens S, Verhelst X, Van Nieuwenhove Y, Praet M, Hoorens A, Van Steenkiste C, Van Vlierberghe H, Lapauw B, Geerts A.

Int J Obes (Lond). 2017 Aug;41(8):1207-1213. doi: 10.1038/ijo.2017.102. Epub 2017 May 2.

PMID:
28461687
42.

Synthesis, in vitro and in vivo evaluation of 3β-[18F]fluorocholic acid for the detection of drug-induced cholestasis in mice.

De Lombaerde S, Neyt S, Kersemans K, Verhoeven J, Devisscher L, Van Vlierberghe H, Vanhove C, De Vos F.

PLoS One. 2017 Mar 8;12(3):e0173529. doi: 10.1371/journal.pone.0173529. eCollection 2017.

43.

Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection.

Bourgeois S, Van Vlierberghe H, Moreno C, Orlent H, Nevens F, Arastéh K, Horsmans Y, Schattenberg JM, Buggisch P, Francque S, Vijgen L, Kakuda TN, Hoeben E, Luo D, Vandebosch A, Jacquemyn B, Van Remoortere P, Verloes R.

BMC Gastroenterol. 2017 Feb 10;17(1):26. doi: 10.1186/s12876-017-0580-2.

44.

Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma.

Personeni N, Giordano L, Abbadessa G, Porta C, Borbath I, Daniele B, Van Laethem JL, Van Vlierberghe H, Trojan J, De Toni EN, Gasbarrini A, Lencioni M, Lamar ME, Wang Y, Shuster D, Schwartz B, Santoro A, Rimassa L.

Oncotarget. 2017 Feb 28;8(9):14408-14415. doi: 10.18632/oncotarget.14797.

45.

Modulation of the Unfolded Protein Response by Tauroursodeoxycholic Acid Counteracts Apoptotic Cell Death and Fibrosis in a Mouse Model for Secondary Biliary Liver Fibrosis.

Paridaens A, Raevens S, Devisscher L, Bogaerts E, Verhelst X, Hoorens A, Van Vlierberghe H, van Grunsven LA, Geerts A, Colle I.

Int J Mol Sci. 2017 Jan 20;18(1). pii: E214. doi: 10.3390/ijms18010214.

46.

Refractory subacute steatohepatitis after biliopancreatic diversion.

Lefere S, Hoorens A, Raevens S, Troisi R, Verhelst X, Van Vlierberghe H, Geerts A.

Hepatology. 2017 Jul;66(1):289-291. doi: 10.1002/hep.29038. Epub 2017 May 9. No abstract available.

PMID:
28073162
47.

A Glycomics-Based Test Predicts the Development of Hepatocellular Carcinoma in Cirrhosis.

Verhelst X, Vanderschaeghe D, Castéra L, Raes T, Geerts A, Francoz C, Colman R, Durand F, Callewaert N, Van Vlierberghe H.

Clin Cancer Res. 2017 Jun 1;23(11):2750-2758. doi: 10.1158/1078-0432.CCR-16-1500. Epub 2016 Dec 16.

48.

Combination of tauroursodeoxycholic acid and N-acetylcysteine exceeds standard treatment for acetaminophen intoxication.

Paridaens A, Raevens S, Colle I, Bogaerts E, Vandewynckel YP, Verhelst X, Hoorens A, van Grunsven LA, Van Vlierberghe H, Geerts A, Devisscher L.

Liver Int. 2017 May;37(5):748-756. doi: 10.1111/liv.13261. Epub 2016 Oct 25.

PMID:
27706903
49.

Macrophage Depletion Attenuates Extracellular Matrix Deposition and Ductular Reaction in a Mouse Model of Chronic Cholangiopathies.

Best J, Verhulst S, Syn WK, Lagaisse K, van Hul N, Heindryckx F, Sowa JP, Peeters L, Van Vlierberghe H, Leclercq IA, Canbay A, Dollé L, van Grunsven LA.

PLoS One. 2016 Sep 12;11(9):e0162286. doi: 10.1371/journal.pone.0162286. eCollection 2016.

50.

Comments on the impact of genotyping method on the subtype distribution of HCV genotype 1.

Van den Borre C, Schuermans W, Van Vlierberghe H, Geerts A, Verhelst X, Padalko E.

J Clin Virol. 2016 Oct;83:54-5. doi: 10.1016/j.jcv.2016.08.291. Epub 2016 Aug 20. No abstract available.

PMID:
27591556

Supplemental Content

Loading ...
Support Center